Interpretation of the NCCN clinical practice guidelines in oncology for lung cancer screening (version 2.2023)
- VernacularTitle:2023年第2版《NCCN肿瘤临床实践指南：肺癌筛查》更新解读
- Author:
Guoqing LUO
1
;
Wenjie WANG
1
;
Xiao LU
1
;
Ning LI
1
;
Qing GENG
1
Author Information
1. Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, P. R. China
- Publication Type:Journal Article
- Keywords:
Lung cancer screening;
NCCN guideline;
guideline interpretation
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2023;30(09):1217-1223
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the malignant tumor with the highest incidence rate in men and the highest mortality rate in men and women in China, and the incidence and mortality rates are still increasing. Lung cancer screening is an important initiative for early detection of lung cancer and improvement of prognosis. The National Comprehensive Cancer Network (NCCN) updates the NCCN Clinical Practice Guidelines for Lung Cancer Screening annually, and the 2023 V2 edition was released in May 2023. The guidelines are based on the latest research advances and high-level evidence-based medical evidence to establish screening criteria for lung cancer, especially for non-small cell lung cancer, which is the most common and highly regarded type of lung cancer, and has received widespread attention from physicians worldwide. In this article, the latest version of the guideline will be interpreted based on China's national situation and Chinese lung cancer screening guidelines, with the aim of providing an updated reference for lung cancer screening in China.
